Does the media favor REGN or ALNY?

In the previous week, Regeneron Pharmaceuticals had 51 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 75 mentions for Regeneron Pharmaceuticals and 24 mentions for Alnylam Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.89 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 47 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALNY or ARGX?

In the previous week, argenex had 18 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 42 mentions for argenex and 24 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat argenex's score of 0.81 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive argenex 13 Very Positive mention(s) 9 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALNY or MRNA?

In the previous week, Moderna had 90 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 114 mentions for Moderna and 24 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat Moderna's score of 0.38 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 45 Very Positive mention(s) 18 Positive mention(s) 14 Neutral mention(s) 18 Negative mention(s) 14 Very Negative mention(s) Neutral

Does the media refer more to ALNY or NTRA?

In the previous week, Natera had 7 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 31 mentions for Natera and 24 mentions for Alnylam Pharmaceuticals. Natera's average media sentiment score of 1.34 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Natera 25 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to RVMD or ALNY?

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Revolution Medicines. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 12 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.37 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Alnylam Pharmaceuticals (ALNY) Competitors

$236.22 +6.92 (+3.02%)

As of 08/21/2026 04:00 PM Eastern

Compare

ALNY vs. REGN, ARGX, MRNA, NTRA, and RVMD

Should you buy Alnylam Pharmaceuticals stock or one of its competitors? Alnylam Pharmaceuticals's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.99	$4.50B	$40.46	20.61
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

In the previous week, Regeneron Pharmaceuticals had 51 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 75 mentions for Regeneron Pharmaceuticals and 24 mentions for Alnylam Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.89 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	47 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals presently has a consensus target price of $801.70, indicating a potential downside of 3.88%. Alnylam Pharmaceuticals has a consensus target price of $386.62, indicating a potential upside of 63.67%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96

Regeneron Pharmaceuticals has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to argenex?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

argenex has lower revenue, but higher earnings than Alnylam Pharmaceuticals. argenex is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91
argenex	$4.25B	15.31	$1.29B	$26.04	39.93

In the previous week, argenex had 18 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 42 mentions for argenex and 24 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat argenex's score of 0.81 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	13 Very Positive mention(s)	9 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 32.19% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
argenex	32.19%	43.59%	36.66%

Alnylam Pharmaceuticals presently has a consensus price target of $386.62, indicating a potential upside of 63.67%. argenex has a consensus price target of $1,118.28, indicating a potential upside of 7.55%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

argenex beats Alnylam Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Moderna?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Alnylam Pharmaceuticals currently has a consensus target price of $386.62, suggesting a potential upside of 63.67%. Moderna has a consensus target price of $69.50, suggesting a potential downside of 52.09%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Moderna had 90 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 114 mentions for Moderna and 24 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat Moderna's score of 0.38 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	45 Very Positive mention(s)	18 Positive mention(s)	14 Neutral mention(s)	18 Negative mention(s)	14 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Moderna's net margin of -141.43%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Moderna	-141.43%	-28.30%	-19.39%

Alnylam Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91
Moderna	$1.94B	29.79	-$2.82B	-$7.99	N/A

Summary

Alnylam Pharmaceuticals beats Moderna on 13 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Natera?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Natera had 7 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 31 mentions for Natera and 24 mentions for Alnylam Pharmaceuticals. Natera's average media sentiment score of 1.34 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Natera's net margin of -7.11%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Natera	-7.11%	-11.38%	-7.87%

Alnylam Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Alnylam Pharmaceuticals currently has a consensus target price of $386.62, suggesting a potential upside of 63.67%. Natera has a consensus target price of $319.38, suggesting a potential downside of 3.81%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Alnylam Pharmaceuticals beats Natera on 10 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Revolution Medicines currently has a consensus price target of $167.89, suggesting a potential downside of 19.85%. Alnylam Pharmaceuticals has a consensus price target of $386.62, suggesting a potential upside of 63.67%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Revolution Medicines. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 12 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.37 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Revolution Medicines' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Alnylam Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,877.00	-$1.13B	-$8.82	N/A
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91

Revolution Medicines has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Revolution Medicines on 11 of the 17 factors compared between the two stocks.

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALNY vs. The Competition

Export

Metric	Alnylam Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.61B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	43.91	11.62	272.88	24.24
Price / Sales	6.58	1,338.17	618.96	99.81
Price / Cash	84.48	105.14	78.62	53.99
Price / Book	23.34	16.80	13.05	6.20
Net Income	$313.75M	-$12.50M	$3.47B	$348.59M
7 Day Performance	3.31%	3.29%	2.09%	0.08%
1 Month Performance	-12.10%	8.23%	6.64%	3.88%
1 Year Performance	-48.01%	55.05%	25.02%	16.98%

Alnylam Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALNY Alnylam Pharmaceuticals	4.9376 of 5 stars	$236.22 +3.0%	$386.62 +63.7%	-48.0%	$31.61B	$4.80B	43.91	2,770	News Coverage Analyst Upgrade
REGN Regeneron Pharmaceuticals	4.0826 of 5 stars	$837.60 +1.3%	$801.70 -4.3%	+41.5%	$86.24B	$14.34B	20.70	15,410	Trending News Ex-Dividend
ARGX argenex	4.2633 of 5 stars	$1,051.33 +1.3%	$1,118.28 +6.4%	+57.5%	$65.77B	$4.25B	40.37	1,863	Trending News Analyst Forecast Analyst Revision
MRNA Moderna	1.6445 of 5 stars	$146.10 +9.6%	$69.50 -52.4%	+434.9%	$58.33B	$2.21B	N/A	4,700	Trending News Analyst Upgrade Options Volume High Trading Volume
NTRA Natera	2.5992 of 5 stars	$328.89 +1.2%	$319.38 -2.9%	+100.5%	$47.41B	$2.31B	N/A	6,140	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALNY) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to argenex?

Summary

How does Alnylam Pharmaceuticals compare to Moderna?

Summary

How does Alnylam Pharmaceuticals compare to Natera?

Summary

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Which has preferable valuation and earnings, REGN or ALNY?

Is REGN or ALNY more profitable?

Does the media favor REGN or ALNY?

Do analysts rate REGN or ALNY?

Which has more volatility & risk, REGN or ALNY?

Do institutionals and insiders believe in REGN or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to argenex?

Which has more risk & volatility, ALNY or ARGX?

Which has better earnings and valuation, ALNY or ARGX?

Does the media refer more to ALNY or ARGX?

Is ALNY or ARGX more profitable?

Do analysts prefer ALNY or ARGX?

Do insiders and institutionals believe in ALNY or ARGX?

Summary

How does Alnylam Pharmaceuticals compare to Moderna?

Do analysts recommend ALNY or MRNA?

Does the media refer more to ALNY or MRNA?

Is ALNY or MRNA more profitable?

Which has more risk and volatility, ALNY or MRNA?

Do insiders and institutionals have more ownership in ALNY or MRNA?

Which has preferable valuation & earnings, ALNY or MRNA?

Summary

How does Alnylam Pharmaceuticals compare to Natera?

Do institutionals and insiders have more ownership in ALNY or NTRA?

Does the media refer more to ALNY or NTRA?

Is ALNY or NTRA more profitable?

Which has stronger valuation & earnings, ALNY or NTRA?

Which has more volatility and risk, ALNY or NTRA?

Do analysts rate ALNY or NTRA?

Summary

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Do institutionals & insiders have more ownership in RVMD or ALNY?

Do analysts prefer RVMD or ALNY?

Does the media refer more to RVMD or ALNY?

Is RVMD or ALNY more profitable?

Which has higher earnings & valuation, RVMD or ALNY?

Which has more risk and volatility, RVMD or ALNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools